$680 Million is the total value of Broadfin Capital, LLC's 50 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IWM | New | ISHARES TRput | $67,420,000 | – | 400,000 | +100.0% | 9.92% | – |
| XBI | New | SPDR SERIES TRUSTput | $15,339,000 | – | 160,000 | +100.0% | 2.26% | – |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $15,156,000 | – | 850,000 | +100.0% | 2.23% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $11,821,000 | – | 895,553 | +100.0% | 1.74% | – |
| XENT | New | INTERSECT ENT INC | $6,733,000 | – | 234,200 | +100.0% | 0.99% | – |
| ANGO | New | ANGIODYNAMICS INC | $6,284,000 | – | 289,035 | +100.0% | 0.92% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INcall | $5,700,000 | – | 150,000 | +100.0% | 0.84% | – |
| IDRA | New | IDERA PHARMACEUTICALS INC | $5,607,000 | – | 629,340 | +100.0% | 0.82% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $5,444,000 | – | 62,200 | +100.0% | 0.80% | – |
| TSRO | New | TESARO INC | $4,084,000 | – | 104,700 | +100.0% | 0.60% | – |
| DXCM | New | DEXCOM INC | $3,462,000 | – | 24,200 | +100.0% | 0.51% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $3,317,000 | – | 150,000 | +100.0% | 0.49% | – |
| VRAY | New | VIEWRAY INC | $2,340,000 | – | 250,000 | +100.0% | 0.34% | – |
| LJPC | New | LA JOLLA PHARMACEUTICAL COcall | $2,013,000 | – | 100,000 | +100.0% | 0.30% | – |
| VCEL | New | VERICEL CORP | $1,876,000 | – | 132,600 | +100.0% | 0.28% | – |
| OMED | New | ONCOMED PHARMACEUTICALS INC | $424,000 | – | 200,000 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.